top glp 1 drug companies 3 at the Forefront of the GLP-1 Pill Wars GLP-1 Medications for Weight Loss:

August 15, 2022

Inflammation Bowel Dis

SURMOUNT-1 demonstrated 15%, 19.5%, and 20.9% body weight reduction at 5, 10, and 15 mg respectively over 72 weeks FDA approvals : Mounjaro (T2D, May 2022) and Zepbound (obesity, November 2023) Cardiovascular outcomes : SURPASS-CVOT in progress to evaluate cardiovascular safety and efficacy Global availability : Approved in US, EU, and numerous international markets Side Effects and Safety Comparison# Mazdutide Side Effects# GI effects : Nausea, diarrhea, and vomiting consistent with GLP-1 class

Look for human evidence, not only exciting mechanisms or popularity

Priority date: 12 November 1996

I think its important to note, however, that this does not invalidate the initial weight loss or the potential popularity of these drugs - nor the chances that patients may stay on them indefinitely